| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-11-29 |
| タイトル |
|
|
タイトル |
Development of a simple and objective prognostication model for patients with advanced solid malignant tumors treated with immune checkpoint inhibitors: A pan-cancer analysis |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Sano, Asuka
Inoue, Yusuke
Kikuchi, Hirotoshi
Fukuchi, Kensuke
Funai, Kazuhito
Imai, Atsushi
Matsushita, Yuto
Tamura, Keita
Kitagawa, Masatoshi
Miyake, Hideaki
|
| 書誌情報 |
en : Targeted Oncology
巻 17,
号 5,
p. 583-589,
発行日 2022-09
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| 権利 |
|
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s11523-022-00911-z |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background Systemic therapy using immune checkpoint inhibitors (ICIs) has recently become prevalent in the treatment of patients with various types of advanced cancers; however, difficulties are still associated with predicting the outcomes of patients receiving ICIs due to heterogenous responses to these agents. Therefore, the objective of the present study was to develop a prognostic model for advanced cancer patients treated with ICIs.
Patients and methods This study retrospectively analyzed the impact of clinical parameters on overall survival (OS) in 329 patients with several advanced solid malignant tumors who received systemic therapy using ICIs.
Results The primary tumors of 329 patients were as follows: lung (n=89), kidney (n=70), urinary tract (n=52), skin (n=50), stomach (n=30), esophagus (n=21), and head and neck (n=17). Median OS after the introduction of ICIs was 17.3 months. Among the factors that correlated with OS in a univariate analysis, body mass index, C-reactive protein, hemoglobin, lymphocytes, and platelets were identified as independent predictors of OS in a multivariate analysis. Following the classification of patients into 3 groups based on positive numbers of these independent risk factors, median OS was not reached in the favorable risk group with 0 or 1 risk factor (n=76), 19.5 months in the intermediate-risk group with 2 or 3 risk factors (n=182), and 8 months in the poor risk group (n=71) with 4 or 5 risk factors.
Conclusions Although this is a simple and objective model, it may be used as a reliable tool to predict the outcomes of advanced cancer patients receiving ICIs across multiple tumor types. |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1776-2596 |
| EISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1776-260X |
| NII書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12157617 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
36094602 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s11523-022-00911-z |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Target Oncol-17-583.pdf (409 KB)
